Inactive Instrument
Kalytera Therapeutics Inc Stock Toronto S.E.
Stocks
CA48349P1036
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.81M 3.34M 3.11M 2.86M 364M 5.46M 36.94M 14.46M 181M 14.3M 13.99M 624M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.46M 3.92M 3.65M 3.35M 426M 6.4M 43.27M 16.94M 211M 16.75M 16.39M 731M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | -10.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 2017-06-20 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 2018-06-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 2021-03-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.00% | -23.08% | - | - | 37 | |
| +0.14% | -0.67% | -0.88% | +11.02% | 47.88B | |
| -2.24% | +0.31% | +393.45% | +615.13% | 39.09B | |
| +1.40% | +3.69% | +12.21% | +46.79% | 36.75B | |
| +13.94% | +20.49% | +22.85% | +7.42% | 40.55B | |
| -0.73% | +3.38% | +4.94% | +41.45% | 27.96B | |
| +0.40% | -0.30% | - | - | 16.77B | |
| -3.12% | +7.39% | +26.03% | +124.08% | 15.94B | |
| +2.39% | -1.64% | +4.74% | +9.95% | 13.55B | |
| +6.79% | +8.17% | -4.97% | -28.52% | 13.81B | |
| Average | +0.90% | +4.64% | +57.30% | +103.42% | 28.03B | |
| Weighted average by Cap. | +2.37% | +5.03% | +73.29% | +125.13% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.05M -13.21M -12.3M -11.32M -1.44B -21.58M -146M -57.13M -713M -56.52M -55.3M -2.46B | 4.21M 2.99M 2.62M 2.44M 2.25M 285M 4.28M 28.97M 11.34M 142M 11.22M 10.97M 489M |
| Net Debt | 704K 500K 438K 408K 376K 47.73M 716K 4.84M 1.9M 23.67M 1.88M 1.84M 81.79M | 920K 653K 573K 534K 491K 62.38M 936K 6.33M 2.48M 30.94M 2.45M 2.4M 107M |
Employees
-
